Study Pain & Neuroscience with Our Antibodies
When discussing our primary antibodies for pain and neuroscience research, we always point to the 20+ years of results. Why wouldn't we? That's quite an accomplishment. Several of these antibodies have been consistently used in published research for over two decades. Over the weekend, two more studies were released using our antibodies in these familiar applications.
Image: Increased expression of mu opioid receptor levels in the ipsilateral lumbar DRGs of CPSS rats.
Researchers from Johns Hopkins University released pain research with the help of our rabbit Mu Opioid Receptor antibody (cat. RA10104). The paper introduced a rat model to study chronic pain after spine surgery (CPSS). By performing surgery on the rats and looking for symptoms of CPSS after the procedure, it provides a model to study the mechanisms of the disorder. You can read the full paper here.
Neuromics Products in Parkinson's Disease Research
At the core of the Neuromics portfolio are reagents with applications in neuroscience research. As a result, we see a large portion of references relating to neurodegenerative diseases, the brain, pain, and other neuroscience fields.
And while our collection of customer publications proves that our products can be used for so much more (see for yourself here), that theme of neuroscience research continued this past week. Two publications were released using our research tools in Parkinson's disease (PD) studies that we'd like to highlight.
Image: GFAP staining (cat. RA22101) of various parts of the PD mouse brain.
In the first study, researchers from Korea used our Rabbit GFAP Polyclonal Antibody (cat. RA22101). They evaluated various antihistamines as potential therapies for patients with PD. After analyzing South Korean patient data and using various animal models, they found that fexofenadine is a potentially effective option to treat PD. Our antibody was used to stain various parts of the mouse brain in a PD model. We encourage you to check out the full publication here.
Our Products Crush Pain & Cancer Research
Over the past few weeks, we've seen a bunch of new publications come through from customers highlighting the capabilities of our many products. These include two studies using some of our highly touted pain research antibodies in migraine and neuropathic pain research. Additionally, one of our primary human cell types was utilized in pancreatic cancer research. You can explore all citations using Neuromics products here.
In the first piece of research, migraine researchers used two of our Neuropeptide Y (NPY) receptor antibodies. The investigators injected mice with glyceryl trinitrate (GTN) in the medial habenula (MHb) to produce a migraine mouse model. Upon microinjections of NPY, the signs of migraine decreased in the GTN mice. Using our Rabbit Polyclonal NPY Y1 Receptor Antibody (cat. RA24506) and Rabbit Polyclonal NPY Y2 Receptor Antibody (cat. RA14112), the scientist observed activation of NPY Y1 receptors, but not NPY Y2 receptors.
Image: Immunofluorescent staining showing the expression of the Y1 receptor (cat. RA24506) and Y2 receptor (cat. RA14112) in the MHb of GTN mice after microinjections of NPY.
Endless Antibody Applications
We often highlight the countless areas of study that our antibodies can help researchers. We encourage you to check out all our primary antibodies here along with the many applications they've been used for here.
Now, the three most prominent and common uses for our antibodies are in cancer, neuroscience, and pain research. Well, what do you know? Already this month, new research has been released utilizing our antibodies in those three corresponding areas. We'd like to highlight those studies below.
Image: Staining of various glioblastoma cell lines with Neuromics Humanin antibody (cat. RA19000).
In the first study, Korean researchers used our Humanin rabbit polyclonal antibody (cat. RA19000) to study glioblastoma progression. In their release of preliminary research, the investigators found humanin to encourage glioblastoma progression via the integrin alpha V (ITGAV)–TGF beta (TGF) signaling axis. Read the full publication here.
Another Pain Antibody Pub
A couple months ago, we published a blog post highlighting the 20+ years of results our pain antibodies have demonstrated (learn more here). It didn't take long into 2023 to add on another year to the total. Earlier this month, researchers from the University of Texas Health Science Center at San Antonio published preliminary findings with the help of Neuromics' Guinea Pig VR1 C-Terminus/TRPV1 antibody (cat. GP14100).
Image: Immunofluorescent images of WGA and TRPV1 (cat. GP14100) staining of TG tissues in male and female mice with colocalization of TRPV1 and WGA indicated with arrows.
The researchers noted that orofacial pain is clinically understood to be more common in females than males. However, despite this understanding, no research had been done to look at what factors cause this occurrence. Using mice as a model, the investigators began to characterized the sex-specific differences in gene expression, biological pathways, and molecular function of tongue sensory neurons. Our antibody played a big part in their analysis. We encourage you to check out the full publication below to learn more about their findings.
